ZYBERNO
Stock Report
Updated Sep 1, 2026

BIOTRICITY INC. (BTCY)

Healthcare • OTC

$0.12

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
25.0/100
POOR BUSINESS
BIOTRICITY INC. (BTCY) scores 25/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
Margin of Safety unavailable — insufficient data for the owner-earnings DCF.
Is the market underestimating or overestimating what this business is capable of going forward?
+2.0%
Fairly Priced
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):AVERAGE (9.6%)
Return on Capital (Capital Efficiency):EXCELLENT (21.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BIOTRICITY INC. (BTCY) stock report — Zyberno Score 25/100 (POOR BUSINESS). Full financial analysis on Zyberno.

According to Zyberno's DCF model, BIOTRICITY INC. (BTCY) shows a Brina Gap of +2.0%, which strengthens the case: based on the company's ROIC (21.2%) and reinvestment rate (-0.5%), the business can fundamentally grow at -0.1% — but the current enterprise value implies the market expects -2.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.12
Market Cap:$2.86M

Valuation Multiples (2)

P/S Ratio:0.17x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$11.95M
Ev Ebitda Ratio:7.60x

Price Action & Momentum (3)

Momentum Percentile:4 / 100
% of 52-Week High:16.5%
B. Profitability Assessment

Return Metrics (6)

ROA:-44.0%
Reinvestment Rate:-0.5%
Fundamental Growth Rate (g):-0.1%
Market-Implied Growth Rate:-2.1%

Margin Analysis (3)

Operating Margin Ttm:9.6%
Net Margin Ttm:-16.4%
Ebitda Margin:9.6%

TTM Performance (3)

Gross Margin Ttm:81.5%
Operating Margin Ttm:9.6%
Net Margin Ttm:-16.4%

Yield Metrics (2)

Earnings Yield:-$113.79
Dividend Yield:22.5%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-193.5%
Latest Earnings Filed:2026-08-19

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):16.4%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):-8.5%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.15x
Quick Ratio:0.11x
Cash Ratio:0.01x

Leverage Analysis (1)

Debt To Ebitda:6.07x

Coverage Ratios (2)

Interest Coverage Ratio:0.50x
Times Interest Earned:0.50

Capital Structure (4)

Working Capital:-31,746,528.00
Cash And Cash Equivalents:466,503.00
Long Term Debt:$252.17K
Net Debt:$9.09M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $16.40M
Linear Growth: 16.4%
📊 Click to view full BTCY Revenue analysis & methodology →
Cost Of Revenue Ttm:$3.04M

Profitability Breakdown (2)

Gross profit TTM: $13.36M
Linear Growth: 30.2%
📊 Click to view full BTCY Gross Profit analysis & methodology →
Operating income TTM: $1.57M
Linear Growth: -8.5%
📊 Click to view full BTCY Operating Income analysis & methodology →

Bottom Line Performance (3)

-$2.69M
Income Before Tax:-$2.69M
Ebitda Ttm:1,573,312.00

Operating Expenses (5)

Operating Expenses:11,795,459.00
R And D Expense:2,741,478.00
Sga Expense:9,053,981.00
Income Tax Expense:$0.00
Interest Expense:3,363,449.00

Expense Ratios (3)

R And D To Revenue Percentage:64.1%
Sga To Revenue Percentage:211.7%
Ebitda Margin:9.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$6.02M
Current Assets:$5.60M
Ppe Net:29,767.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:41,430,370.00
Current Liabilities:37,342,570.00
Long Term Debt:$252.17K
Short Term Debt:$9.30M

Equity & Capital (3)

Equity:-$35.41M
Retained Earnings:-$143.64M
Common Stock:125,000,000.00

Working Capital Items (3)

Accounts Receivable:2,397,736.00
Inventory:1,425,002.00
Accounts Payable:9,301,716.00

Special Items (2)

Contract Liabilities:33,537.00
Stock Based Compensation:339,970.00
C. Cash Flow Analysis

Operating Activities (2)

$161.66K$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:-$190.94K
Dividends Paid Ttm:602,969.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:125,227.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:5,953.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.13
-$0.13
Earnings Per Share Ttm:-$0.12

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.71
Operating Cash Flow Per Share:-$0.03

Book Value & Capital (2)

Book Value Per Share:-$1.53
Cash Per Share:0.02

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:2.68x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:6.84x
Days Sales Outstanding Ttm:53.36

Inventory Management (2)

Inventory Turnover Ttm:2.13x
Days Inventory Outstanding Ttm:171.18

Payables & Cash Cycle (2)

Days Payable Outstanding:1,117.41
Cash Conversion Cycle:-892.87
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (4)

Reinvestment Rate:-0.5%
Fundamental Growth Rate (g):-0.1%
Market-Implied Growth Rate:-2.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):16.4%
Operating Income Growth Rate (Linear):-8.5%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):30.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:BTCY
Company Name:BIOTRICITY INC.
Sector:Healthcare
Industry:Medical Devices
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:23.10M
Shares Outstanding Basic:23.10M
Shares Outstanding Diluted:23.10M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 20:20:25 UTC
Data Timestamp:2026-08-22T09:40:25.397927
Scroll to Top